Left Ventricular Thrombus Formation After ST-Segment-Elevation Myocardial Infarction: Insights From a Cardiac Magnetic Resonance Multicenter Study

Circ Cardiovasc Imaging. 2015 Oct;8(10):e003417. doi: 10.1161/CIRCIMAGING.115.003417.


Background: Data on left ventricular (LV) thrombus formation after primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction (STEMI) are scarce. The aims of this study were to assess the (1) incidence of LV thrombi using cardiac magnetic resonance in a multicenter cohort of STEMI patients and (2) prognostic relevance of LV thrombi at 1-year follow-up.

Methods and results: In total, 738 STEMI patients reperfused by primary angioplasty were enrolled in 8 centers. Cardiac magnetic resonance was completed within 1 week after infarction. Central core laboratory-masked analyses for the presence of LV thrombi were performed. The primary clinical end point was the occurrence of major adverse cardiac events within 1 year. LV thrombi were detected in 26 patients (3.5%) in the overall cohort and in 7.1% in anterior STEMI patients. The presence of thrombi was associated with larger infarcts (P<0.001), less myocardial salvage (P<0.01), impaired LV ejection fraction (P<0.001), and more pronounced late microvascular obstruction (P=0.002). The presence of thrombi was independently associated with the incidence of major adverse cardiac events at 12 months (hazard ratio, 2.73; 95% confidence interval, 1.11-6.73; P=0.03).

Conclusions: In this multicenter cohort of patients with STEMI, thrombus prevalence assessed by cardiac magnetic resonance was 3.5% and associated with decreased myocardial salvage, larger infarcts, and more pronounced reperfusion injury. Importantly, LV thrombus was independently associated with major adverse cardiac events at 1-year follow-up.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00712101.

Keywords: incidence; myocardial infarction; percutaneous coronary intervention; prevalence; prognosis.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Abciximab
  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Disease Progression
  • Electrocardiography*
  • Female
  • Follow-Up Studies
  • Heart Diseases / diagnosis
  • Heart Diseases / drug therapy
  • Heart Diseases / etiology
  • Heart Ventricles / pathology*
  • Heart Ventricles / physiopathology
  • Humans
  • Immunoglobulin Fab Fragments / administration & dosage
  • Injections, Intra-Arterial
  • Magnetic Resonance Imaging, Cine / methods*
  • Male
  • Middle Aged
  • Myocardial Infarction / complications*
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / surgery
  • Percutaneous Coronary Intervention
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Prognosis
  • Prospective Studies
  • Thrombosis / diagnosis*
  • Thrombosis / drug therapy
  • Thrombosis / etiology
  • Ventricular Function, Left


  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Abciximab

Associated data

  • ClinicalTrials.gov/NCT00712101